Herpesvirus Antiviral Resistance
Database

TOP

• Short name: Antiviral Res
• References:
• -A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017).
• -Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020).
• -Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016).
• -Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012).
• -First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022).
• -Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024).
• -Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013).
• -Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998).
• -Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014).
• -Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016).
• -Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013).
• -Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019).

Mutations: